Firm’s clients will be able to leverage the technology in their companion diagnostic development efforts.
ResearchDx will offer its customers the CompanDx Distiller bioinformatics platform for deriving biomarkers. The firms’ partnership is designed to let clients initiate the development of companion diagnostic tests from the very earliest stages of drug development.
“CompanDX’ unique capabilities allow us to fully integrate bioinformatics into development of a diagnostic product from early in the discovery process,” states ResearchDx founders and principals Philip D. Cotter, Ph.D., and Mathew W. Moore, Ph.D.
ResearchDx, which launched in February and calls itself as a contract diagnostics organization, offers clinical research services to design, produce, and validate diagnostic tests from initial assay conceptualization to regulatory approval.
In March, CompanDx inked a multiyear agreement to use the CLIA-certified laboratory services of Clinical Reference Laboratory in the continued development of its Distiller technology, specifically in the development of the first “Time to Event” panel of breast cancer biomarkers, and companion diagnostics.